Keyphrases
Crohn's Disease
100%
Inflammatory Bowel Disease
91%
Infliximab
39%
Ulcerative Colitis
21%
Anti-tumor Necrosis Factor (anti-TNF)
19%
Vedolizumab
18%
Confidence Interval
13%
Clinical Remission
13%
Anti-drug Antibodies
13%
Capsule Endoscopy
12%
Magnetic Resonance Enterography
12%
Systematic Meta-analysis
12%
Adalimumab
12%
Clinical Response
11%
Loss of Response
11%
Immunomodulator
11%
Meta-analysis
11%
Video Capsule Endoscopy
10%
Small Intestine
10%
Mucosal Healing
10%
Odds Ratio
9%
Israel
8%
Remission
8%
Inflammation
8%
Drug Levels
8%
Infliximab Therapy
7%
Randomized Controlled Trial
7%
Israeli
7%
Infliximab Levels
7%
Immunogenicity
6%
Thiopurines
6%
Tumor Necrosis Factor-α
6%
CT-P13
6%
Fecal Calprotectin
6%
Disease Activity
6%
Anti-infliximab Antibodies
6%
Crohn's
6%
Antibodies to Infliximab
6%
Ustekinumab
6%
Small Bowel Crohn's Disease
6%
Combination Therapy
5%
Trough Level
5%
Lewis Score
5%
Hospitalization
5%
Pharmacokinetics
5%
Biological Treatment
5%
Retrospective Cohort Study
5%
Clinical Outcomes
5%
Area under the Curve
5%
Celiac Disease
5%
Medicine and Dentistry
Crohn's Disease
68%
Inflammatory Bowel Disease
56%
Ulcerative Colitis
23%
Capsule Endoscopy
21%
Infliximab
20%
Disease
20%
Patient with Inflammatory Bowel Disease
19%
Patient with Crohn's Disease
17%
Tumor Necrosis Factor
16%
Systematic Review
13%
Meta-Analysis
12%
Vedolizumab
12%
Magnetic Resonance Enterography
12%
Odds Ratio
9%
Retrospective Cohort Study
7%
Faecal Calprotectin
7%
Immunomodulating Agent
7%
Diagnosis
7%
Colonoscopy
6%
Biological Product
6%
Trough Level
6%
Biological Marker
5%
Disease Activity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
62%
Crohn's Disease
62%
Infliximab
36%
Ulcerative Colitis
25%
Remission
24%
Tumor Necrosis Factor
22%
Disease
11%
Vedolizumab
10%
Immunomodulating Agent
9%
Inflammation
9%
Adalimumab
9%
Randomized Controlled Trial
8%
Biological Product
8%
Cohort Study
8%
Combination Therapy
7%
Mercaptopurine
7%
Biological Marker
7%
Immunogenicity
6%
Trough Level
6%
Tumor Necrosis Factor Inhibitor
5%
Calgranulin
5%
Monotherapy
5%
Biosimilar Agent
5%